Sarepta Therapeutics (SRPT) Receives Media Impact Rating of 0.18

Media coverage about Sarepta Therapeutics (NASDAQ:SRPT) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sarepta Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.4061545521188 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern’s rankings:

Several equities analysts have commented on SRPT shares. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 25th. Zacks Investment Research downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 9th. JPMorgan Chase reiterated an “overweight” rating and issued a $75.00 target price (up from $63.00) on shares of Sarepta Therapeutics in a research report on Wednesday, February 21st. Finally, Barclays reiterated a “hold” rating and issued a $55.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, January 23rd. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $78.87.



Shares of SRPT opened at $82.81 on Friday. Sarepta Therapeutics has a 1 year low of $28.82 and a 1 year high of $84.37. The company has a quick ratio of 12.96, a current ratio of 13.91 and a debt-to-equity ratio of 0.54. The stock has a market cap of $5,127.44, a PE ratio of -50.49 and a beta of 1.29.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The company had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. During the same quarter last year, the business earned ($0.71) earnings per share. Sarepta Therapeutics’s revenue was up 961.1% compared to the same quarter last year. research analysts anticipate that Sarepta Therapeutics will post -1.18 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://dakotafinancialnews.com/2018/04/13/sarepta-therapeutics-srpt-receives-media-impact-rating-of-0-18.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply